Tociluzumab

DRUG2 trials

Sponsors

Hoffmann-La Roche, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic Granulomatous DiseaseRelapsed or Refractory Follicular Lymphoma

Phase 1

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

RecruitingNCT05463133

National Institute of Allergy and Infectious Diseases (NIAID)Chronic Granulomatous Disease

Start: 2022-07-08End: 2032-12-31Target: 50Updated: 2026-05-14

Phase 3

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Active, not recruitingNCT04712097

Hoffmann-La RocheRelapsed or Refractory Follicular Lymphoma

Start: 2021-10-27End: 2029-12-31Updated: 2026-07-10

Related Papers

Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study

Blood2025-11-03

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Journal of Clinical Oncology2024-03-2852 citations

CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.

Journal of Clinical Oncology2022-06-0111 citations

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

HemaSphere2022-06-015 citations